DE602006012513D1 - Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin - Google Patents
Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocinInfo
- Publication number
- DE602006012513D1 DE602006012513D1 DE602006012513T DE602006012513T DE602006012513D1 DE 602006012513 D1 DE602006012513 D1 DE 602006012513D1 DE 602006012513 T DE602006012513 T DE 602006012513T DE 602006012513 T DE602006012513 T DE 602006012513T DE 602006012513 D1 DE602006012513 D1 DE 602006012513D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- headaches
- administering oxytocin
- oxytocin
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010019233 Headaches Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101800000989 Oxytocin Proteins 0.000 title abstract 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 229960001723 oxytocin Drugs 0.000 title 1
- 231100000869 headache Toxicity 0.000 abstract 2
- 208000027109 Headache disease Diseases 0.000 abstract 1
- 206010044652 trigeminal neuralgia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71195005P | 2005-08-26 | 2005-08-26 | |
US79400406P | 2006-04-21 | 2006-04-21 | |
PCT/US2006/033500 WO2007025249A2 (en) | 2005-08-26 | 2006-08-28 | Methods for treatment of headaches by administration of oxytocin |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006012513D1 true DE602006012513D1 (de) | 2010-04-08 |
Family
ID=37654909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006012513T Active DE602006012513D1 (de) | 2005-08-26 | 2006-08-28 | Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin |
Country Status (9)
Country | Link |
---|---|
US (9) | US20070093420A1 (de) |
EP (3) | EP2179741B1 (de) |
JP (4) | JP5276982B2 (de) |
AT (1) | ATE458491T1 (de) |
AU (1) | AU2006282799B2 (de) |
CA (2) | CA2620202C (de) |
DE (1) | DE602006012513D1 (de) |
IL (1) | IL189777A0 (de) |
WO (2) | WO2007025249A2 (de) |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8481043B2 (en) * | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
AU2006282799B2 (en) * | 2005-08-26 | 2012-11-29 | Healthpartners Research & Education | Methods for treatment of headaches by administration of oxytocin |
KR101441843B1 (ko) | 2005-10-18 | 2014-09-17 | 내셔날 쥬이쉬 헬스 | 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법 |
ME00419B (me) | 2005-11-14 | 2011-10-10 | Rinat Neuroscience Corp | Antigonistička antitijela usmjerena protiv kalcitonita, peptida povezanog sa genom i postupkom njihovog korišćenja |
US20080261893A1 (en) * | 2006-02-24 | 2008-10-23 | Denise Barbut | Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing |
WO2007120485A2 (en) * | 2006-03-30 | 2007-10-25 | Cinergen, Llc | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor |
GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
US7645767B2 (en) * | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
EP2131651B1 (de) * | 2007-03-12 | 2013-05-22 | Sarentis Therapeutics, Inc. | Topische hornhautschmerzmittel mit neurotensin-rezeptoragonisten |
AU2008224950B2 (en) * | 2007-03-13 | 2013-10-03 | National Jewish Medical And Research Center | Methods for generation of antibodies |
WO2008154337A1 (en) * | 2007-06-08 | 2008-12-18 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
US9707274B2 (en) | 2007-06-08 | 2017-07-18 | Healthpartners Research & Education | Methods for preventing and treating post-traumatic stress disorder (PTSD) |
US20100221200A1 (en) * | 2007-07-17 | 2010-09-02 | The Ohio State University Research Foundation | Compositions and methods for skin care |
RU2010114029A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Астрессин и бета-эндорфин для применения в качестве терапевтических средств |
AU2008303942A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of BFGF 1-24 and optionally (ARG 8) vasopressin to treat eg S. pneumoniae infection |
WO2009040071A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009033489A2 (en) * | 2007-09-11 | 2009-03-19 | Glostrup Hospital | Selective pacl inhibitors for use in the treatment of migraine and headaches |
CA2699222A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
NZ587292A (en) | 2008-03-04 | 2012-09-28 | Pfizer Ltd | Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain |
WO2009145956A2 (en) * | 2008-03-06 | 2009-12-03 | The Trustees Of Columbia University In The City Of New York | Uses of calpain inhibitors to inhibit inflammation |
US20090246273A1 (en) * | 2008-03-27 | 2009-10-01 | Al-Ghananeem Abeer M | Ketorolac Sublingual Spray for the Treatment of Pain |
AU2009246876B2 (en) * | 2008-05-16 | 2015-04-02 | Htyr Acquisition Llc | Antibodies and processes for preparing the same |
FR2932483A1 (fr) * | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
DK2313496T3 (en) * | 2008-07-21 | 2014-12-15 | Taiga Biotechnologies Inc | Anukleære differentiated cells, and method for preparation thereof |
AU2009285547B2 (en) | 2008-08-28 | 2012-05-31 | Taiga Biotechnologies (Abc), Llc | Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
WO2010029555A1 (en) * | 2008-09-12 | 2010-03-18 | Slender Medical, Ltd. | Virtual ultrasonic scissors |
US20110318345A1 (en) * | 2008-09-15 | 2011-12-29 | Optinose As | Nasal delivery |
AU2009305563C1 (en) * | 2008-10-17 | 2015-09-03 | Signature Therapeutics, Inc. | Pharmaceutical compositions with attenuated release of phenolic opioids |
WO2010090628A2 (en) * | 2008-12-08 | 2010-08-12 | Biousian Biotechnology, Inc | Delta-opioid receptor selective analgesics |
WO2010091198A1 (en) * | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
EP2429503A1 (de) * | 2009-05-13 | 2012-03-21 | Protein Delivery Solutions, LLC | Pharmazeutisches system zur transmembranösen abgabe |
US9107876B2 (en) | 2009-07-02 | 2015-08-18 | Yamaguchi University | Surface anesthetic agent |
JP5863650B2 (ja) | 2009-07-27 | 2016-02-16 | ノシセプタ エルエルシー | 疼痛を処置するための方法 |
FR2948809B1 (fr) * | 2009-07-31 | 2012-08-17 | St Microelectronics Rousset | Amplificateur de lecture faible puissance auto-minute |
BR112012004464B8 (pt) | 2009-08-28 | 2021-05-25 | Labrys Biologics Inc | uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica |
JP2013503862A (ja) | 2009-09-08 | 2013-02-04 | シグネーチャー セラピューティクス,インク. | 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 |
EP2512240B1 (de) * | 2009-12-18 | 2018-04-11 | Achelios Therapeutics, Inc. | Verfahren und zusammensetzungen zur behandlung und prävention von trigeminoautonomen zephalgien, migräne und gefässerkrankungen |
US8622993B2 (en) * | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
US20110184322A1 (en) * | 2010-01-22 | 2011-07-28 | Slender Medical Ltd. | Method and device for treatment of keloids and hypertrophic scars using focused ultrasound |
CA2828833C (en) | 2010-03-03 | 2020-11-03 | Neonc Technologies Inc. | Pharmaceutical compositions comprising monoterpenes |
WO2011133178A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug |
US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
WO2011133179A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc | Compositions comprising enzyme-cleavable hydromorphone prodrug |
WO2011133348A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
US8617150B2 (en) | 2010-05-14 | 2013-12-31 | Liat Tsoref | Reflectance-facilitated ultrasound treatment |
US8956346B2 (en) | 2010-05-14 | 2015-02-17 | Rainbow Medical, Ltd. | Reflectance-facilitated ultrasound treatment and monitoring |
US9242122B2 (en) | 2010-05-14 | 2016-01-26 | Liat Tsoref | Reflectance-facilitated ultrasound treatment and monitoring |
US9101569B2 (en) | 2010-05-18 | 2015-08-11 | Universite De Geneve | Methods for the treatment of insulin resistance |
AU2011276170B2 (en) * | 2010-07-06 | 2016-03-10 | Grunenthal Gmbh | Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid |
WO2012083178A1 (en) | 2010-12-17 | 2012-06-21 | Neo Oncology Inc. | Methods and devices for using isoperillyl alcohol |
US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
EP2883543B1 (de) | 2010-08-27 | 2016-11-16 | Neonc Technologies Inc. | Pharmazeutische Zusammensetzungen mit Perillylalcohol-Carbamaten |
GB201015371D0 (en) * | 2010-09-14 | 2010-10-27 | Optinose As | Nasal delivery |
US8647661B1 (en) * | 2010-11-05 | 2014-02-11 | Florida A&M University | Surface modified multilayered nanostructures for dermal delivery |
US8497237B2 (en) | 2011-01-11 | 2013-07-30 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
EP2663187B1 (de) | 2011-01-11 | 2016-06-01 | Signature Therapeutics, Inc. | Zusammensetzungen mit einem enzymspaltbaren oxycodon-prodrug |
US20120183580A1 (en) * | 2011-01-13 | 2012-07-19 | Theralpha | Analgesic Composition for Transbuccal Administration |
US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US10687975B2 (en) * | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
EP2683394B1 (de) | 2011-03-09 | 2021-01-06 | Signature Therapeutics, Inc. | Wirkstoff-prodrugs mit heterocyclischen linkern |
WO2012123819A1 (en) * | 2011-03-15 | 2012-09-20 | Optinose As Et Al | Nasal delivery |
LT2694049T (lt) | 2011-04-05 | 2018-12-27 | GrĆ¼nenthal GmbH | Tapentadolis, skirtas skausmo perėjimo į lėtinį prevencijai |
HUE047342T2 (hu) * | 2011-04-05 | 2020-04-28 | Gruenenthal Gmbh | Tapentadol a trigeminális neuralgiával kapcsolatos fájdalom kezelése során történõ alkalmazásra |
PL3272343T3 (pl) | 2011-04-29 | 2020-07-27 | Grünenthal GmbH | Tapentadol w prewencji i leczeniu depresji i lęku |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
US8987199B2 (en) | 2011-06-15 | 2015-03-24 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
US10813897B2 (en) | 2011-12-27 | 2020-10-27 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US11213500B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US9468599B2 (en) * | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US11213501B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US9962391B2 (en) | 2011-12-27 | 2018-05-08 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
EP2800606A4 (de) * | 2012-01-05 | 2015-07-15 | Beech Tree Labs Inc | Verfahren zur schmerzbehandlung durch verabreichung eines nervenwachstumsfaktors |
US9707414B2 (en) | 2012-02-14 | 2017-07-18 | Rainbow Medical Ltd. | Reflectance-facilitated ultrasound treatment and monitoring |
CA2864606C (en) | 2012-02-15 | 2021-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing diseases and disorders of the central nervous system |
US9789135B2 (en) | 2012-07-20 | 2017-10-17 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
ES2442242B1 (es) * | 2012-08-09 | 2014-11-25 | Biotechnology Institute, I Mas D, S.L. | Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación. |
CN107334525B (zh) | 2012-11-05 | 2019-10-08 | 毕达哥拉斯医疗有限公司 | 受控组织消融 |
US9770593B2 (en) | 2012-11-05 | 2017-09-26 | Pythagoras Medical Ltd. | Patient selection using a transluminally-applied electric current |
JP6284541B2 (ja) * | 2012-11-28 | 2018-02-28 | ネクター セラピューティクス | 長時間作用型トポイソメラーゼi阻害薬による乳癌治療の有効性を評価及び予測する方法 |
US9050330B2 (en) * | 2012-12-06 | 2015-06-09 | Jose C. Ramon-de-Jesus | Method, composition and kit for treating frequent headaches |
US10639439B2 (en) | 2013-01-30 | 2020-05-05 | Midwest Pharmaceuticals, Llc | Smokeless THC and administration method thereof |
US20140294923A1 (en) * | 2013-02-20 | 2014-10-02 | Questcor Pharmaceuticals, Inc. | Acth for treatment of migraine headache |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
JP6283408B2 (ja) | 2013-03-15 | 2018-02-21 | アムジェン インコーポレイテッド | ヒトpac1抗体 |
KR20220119187A (ko) | 2013-05-15 | 2022-08-26 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달 |
US20150086616A1 (en) * | 2013-09-20 | 2015-03-26 | Steven Lehrer | Method for the prevention and treatment of alzheimer's disease |
US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
CA2943551A1 (en) | 2014-03-21 | 2015-09-24 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
EP3139853B1 (de) | 2014-05-07 | 2018-12-19 | Pythagoras Medical Ltd. | Apparat zur gesteuerten gewebeablation |
AU2015277272A1 (en) * | 2014-06-16 | 2017-01-12 | Loewi LLC | Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof |
UY36302A (es) | 2014-09-15 | 2016-04-29 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas |
PL3200773T3 (pl) * | 2014-10-01 | 2018-12-31 | Oxytone Bioscience B.V. | Rozpadająca się w ustach stała farmaceutyczna jednostka dawkowania zawierająca substancję kontrolującą poród |
CN107106640B (zh) * | 2014-10-01 | 2021-06-15 | 奥克希托恩生物科学公司 | 含有分娩控制物质的口服崩解固体药物剂量单元 |
BR112017008097B1 (pt) | 2014-10-20 | 2023-03-28 | Oyster Point Pharma, Inc | Método para tratar condições oculares |
US10388407B2 (en) | 2014-10-21 | 2019-08-20 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
EP3209803A4 (de) | 2014-10-21 | 2018-06-13 | Ubiome, Inc. | Verfahren und zusammensetzungen für mikrobiom-diagnostika und -therapeutika |
MX2017006265A (es) | 2014-11-19 | 2017-08-14 | Optinose As | Administracion intranasal. |
US20170266106A1 (en) * | 2014-12-01 | 2017-09-21 | Achelios Therapeutics, Inc. | Methods and compositions for treating migraine and conditions associated with pain |
PT3242676T (pt) | 2015-01-07 | 2023-12-06 | TONIX Pharmaceuticals Holding Corp | Formulações de ocitocina que contém magnésio e métodos de uso |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
KR20170131405A (ko) | 2015-02-12 | 2017-11-29 | 네온씨 테크놀로지스, 아이엔씨. | 페릴릴 알코올 유도체를 포함하는 의약 조성물 |
WO2016140063A1 (ja) * | 2015-03-04 | 2016-09-09 | 栄研化学株式会社 | オキシトシンの高感度測定法 |
MX2017013113A (es) | 2015-04-16 | 2018-07-06 | Alder Biopharmaceuticals Inc | Anticuerpos anti-pacap y sus usos. |
US10383685B2 (en) | 2015-05-07 | 2019-08-20 | Pythagoras Medical Ltd. | Techniques for use with nerve tissue |
US11207461B2 (en) | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
US11213480B1 (en) | 2015-08-06 | 2022-01-04 | Hikma Pharmaceuticals International Limited | Phenylephrine hydrochloride ready-to-use solution |
WO2017059459A1 (en) | 2015-10-01 | 2017-04-06 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
EP3390447A1 (de) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Pacap-antikörper und verwendungen davon |
MX2018012351A (es) * | 2016-04-12 | 2019-02-07 | Trigemina Inc | Formulaciones de oxitocina que contienen magnesio y metodos de uso. |
SG10202109691UA (en) | 2016-04-15 | 2021-10-28 | Alder Biopharmaceuticals Inc | Anti-pacap antibodies and uses thereof |
CA3019427A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
EP3457975A2 (de) | 2016-05-18 | 2019-03-27 | Pythagoras Medical Ltd. | Spiralförmiger katheter |
WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
WO2018094376A1 (en) * | 2016-11-21 | 2018-05-24 | uBiome, Inc. | Method and system for characterizing a headache-related condition |
CN110267538B (zh) | 2016-11-30 | 2022-04-19 | 尼昂克技术公司 | 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法 |
CA3045017A1 (en) | 2016-12-02 | 2018-06-07 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
US10932711B2 (en) | 2017-02-27 | 2021-03-02 | Payman Sadeghi | Method and system for neurohydrodissection |
US10456419B2 (en) | 2017-02-27 | 2019-10-29 | Payman Sadeghi | Method for treating migraine headaches |
EP3595663A4 (de) | 2017-03-17 | 2021-01-13 | Elysium Therapeutics, Inc. | Mehrfachuntereinheit-opioid-prodrugs mit resistenz gegen überdosierung und missbrauch |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
SG11202002457RA (en) | 2017-09-22 | 2020-04-29 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
US10738110B2 (en) | 2018-01-12 | 2020-08-11 | Amgen Inc. | PAC1 antibodies and uses thereof |
CA3225993A1 (en) | 2018-02-08 | 2019-08-15 | University Of Southern California | The use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier |
US20210346385A1 (en) * | 2018-09-21 | 2021-11-11 | MSB Holdings, Inc | Taste-masked dosage forms |
US11135379B2 (en) | 2019-02-15 | 2021-10-05 | Bn Intellectual Properties, Inc. | Method of delivering pharmaceutical products |
JP2022547365A (ja) | 2019-03-14 | 2022-11-14 | オーエム ファーマ エスエー | 喘息、喘息悪化、アレルギー性喘息及び/又は関連疾患状態を呼吸器疾患に関連する微生物叢で治療及び/又は予防する方法 |
WO2021016190A1 (en) * | 2019-07-19 | 2021-01-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for modulating drug-use disorders |
US11364225B2 (en) * | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
JP2022546703A (ja) * | 2019-08-29 | 2022-11-07 | ニューヨーク ユニバーシティ | 耳鳴りの治療のためのオキシトシン組成物 |
WO2021072055A1 (en) * | 2019-10-11 | 2021-04-15 | Board Of Regents, The University Of Texas System | Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression |
WO2021151100A1 (en) | 2020-01-24 | 2021-07-29 | Aim Immunotech Inc. | Methods, compositions, and vaccines for treating a virus infection |
EP4192436A1 (de) * | 2020-08-10 | 2023-06-14 | Ziropa, Inc. | Zusammensetzungen und verfahren zur topischen verabreichung |
WO2023146579A1 (en) * | 2022-01-27 | 2023-08-03 | Belnap Pharmaceuticals, Llc | Methods of treatment using oxytocin |
WO2024102741A2 (en) * | 2022-11-07 | 2024-05-16 | AEON Biopharma, Inc. | Compositions for use in treating headache disorders |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413A (en) * | 1849-05-01 | Improved method of making wire-strengthened spoons | ||
US464378A (en) * | 1891-12-01 | Toilet-paper holder | ||
US2938891A (en) | 1956-03-30 | 1960-05-31 | Roussel Uclaf | Method of making oxytocin and intermediates thereof |
US3076797A (en) | 1957-07-22 | 1963-02-05 | Roussel Uclaf | Process of producing oxytocin and intermediates obtained thereby |
US4213968A (en) * | 1978-06-05 | 1980-07-22 | Coy David Howard | Enkephalin derivatives |
US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4486441A (en) * | 1982-12-03 | 1984-12-04 | Merrell Toraude Et Compagnie | Pseudotropyl halogeno-benzoates and their use in migraine treatment |
EP0223831B1 (de) | 1985-05-22 | 1992-07-15 | Liposome Technology, Inc. | Verfahren und system zum einatmen von liposomen |
HU906340D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
NZ226557A (en) * | 1987-10-15 | 1990-07-26 | Syntex Inc | Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation |
US4885287A (en) * | 1988-08-09 | 1989-12-05 | University Of Kentucky Research Foundation | Novel method of administering aspirin and dosage forms containing same |
WO1991007947A1 (en) * | 1989-12-05 | 1991-06-13 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
US5624898A (en) * | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
US6407061B1 (en) * | 1989-12-05 | 2002-06-18 | Chiron Corporation | Method for administering insulin-like growth factor to the brain |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
GB9203769D0 (en) * | 1992-02-21 | 1992-04-08 | Sandoz Ltd | Improvements in or relating to organic compounds |
DE4312913A1 (de) * | 1992-10-23 | 1994-10-13 | Knauf Siegfried | Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine |
SE9300937L (sv) * | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
US6054462A (en) * | 1994-04-13 | 2000-04-25 | Janssen Pharmaceutica, N.V. | Intranasal antimigraine compositions |
WO1996020001A1 (fr) * | 1994-12-28 | 1996-07-04 | Teikoku Hormone Mfg. Co., Ltd. | Preparation traversant la muqueuse |
US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
DK0943326T4 (da) * | 1996-02-27 | 2007-01-22 | Teijin Ltd | Pulveragtigt præparat til nasal administration |
US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
SE9701161D0 (sv) * | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use I |
SE9701162D0 (sv) * | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
US6432986B2 (en) * | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US6143278A (en) * | 1998-02-23 | 2000-11-07 | Elkhoury; George F. | Topical application of opioid analgesic drugs such as morphine |
US6090368A (en) * | 1998-03-03 | 2000-07-18 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine |
US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
DE69928563T2 (de) * | 1998-12-09 | 2006-07-27 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Abgeben von neurotropischen Wirkstoffen an das Zentralnervensystem |
WO2000033814A2 (en) | 1998-12-09 | 2000-06-15 | Chiron Corporation | Method for administering agents to the central nervous system |
US6139861A (en) * | 1999-01-14 | 2000-10-31 | Friedman; Mark | Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm |
NZ515783A (en) * | 1999-06-16 | 2004-05-28 | Nastech Pharmaceutical Co | Pharmaceutical formulations and methods comprising intranasal morphine |
JP2001002589A (ja) * | 1999-06-18 | 2001-01-09 | Teijin Ltd | 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物 |
JP2001089359A (ja) * | 1999-09-24 | 2001-04-03 | Toko Yakuhin Kogyo Kk | 鎮痛成分の点鼻用ゲルまたはゾル製剤 |
WO2001041732A1 (en) * | 1999-12-06 | 2001-06-14 | Gore Stanley L | Compositions and methods for intranasal delivery of active agents to the brain |
JP2003516360A (ja) * | 1999-12-09 | 2003-05-13 | カイロン コーポレイション | 中枢神経系およびリンパ系に対するサイトカイン投与方法 |
US6413499B1 (en) * | 2000-01-06 | 2002-07-02 | Bryan M. Clay | Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic |
EP1276475A2 (de) * | 2000-04-28 | 2003-01-22 | Memorial Sloan-Kettering Cancer Center | Topische opioid und lokalanästhetika enthaltende formulierungen und deren verwendung |
US7084126B1 (en) * | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
AU2001262992A1 (en) * | 2000-05-10 | 2002-02-18 | University Of Kentucky Research Foundation | System and method for intranasal administration of opioids |
AU2002211688A1 (en) * | 2000-10-13 | 2002-04-29 | Chiron Corporation | Method for treating ischemic events affecting the central nervous system |
US20070112052A9 (en) * | 2001-01-05 | 2007-05-17 | Larry Caldwell | Methods and compositions for treating headache pain with topical NSAID compositions |
WO2002076388A2 (en) | 2001-03-23 | 2002-10-03 | Albert Einstein College Of Medecine Of Yeshiva University | Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside |
US20020169102A1 (en) | 2001-04-03 | 2002-11-14 | Frey William H. | Intranasal delivery of agents for regulating development of implanted cells in the CNS |
EP1385937A4 (de) * | 2001-04-20 | 2005-11-09 | Chiron Corp | Zuführung von polynukleotidagenzien an das zentralnervensystem |
US7820688B2 (en) * | 2001-04-27 | 2010-10-26 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
US20030104085A1 (en) * | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
US20070004743A1 (en) * | 2002-02-25 | 2007-01-04 | Xiao Linda L | Intranasal administration of mc4-r agonists |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
US7074426B2 (en) * | 2002-03-27 | 2006-07-11 | Frank Kochinke | Methods and drug delivery systems for the treatment of orofacial diseases |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
JP2005527209A (ja) * | 2002-04-22 | 2005-09-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛管理のためのプロテインキナーゼCγのペプチドインヒビター |
EP1504268A2 (de) | 2002-05-02 | 2005-02-09 | Bayer HealthCare AG | Diagnostika und therapeutika für krankheiten, die mit dem oxytocin rezeptor (oxtr) assoziiert sind |
EP1551457A1 (de) * | 2002-07-16 | 2005-07-13 | Elan Pharma International Limited | Flüssige dosierzusammensetzungen von stabilen wirkstoffen in nanoteilchenform |
AU2003273247A1 (en) | 2002-08-30 | 2004-03-19 | Board Of Regents, The University Of Texas System | Non-invasive methods to identify agents for treating pain |
US7065445B2 (en) * | 2002-11-27 | 2006-06-20 | Mobilearia | Vehicle passive alert system and method |
WO2004062563A2 (en) | 2003-01-16 | 2004-07-29 | Université de Lausanne | Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders |
EP1468690B1 (de) * | 2003-03-27 | 2008-10-08 | Pantarhei Bioscience B.V. | Verwendung von Estrogenen zur Behandlung von Männerunfruchtbarkeit |
CA2520655A1 (en) | 2003-04-08 | 2004-11-04 | Biotempt, B.V. | Compositions for mucosal and oral administration comprising hcg fragments |
US20040229025A1 (en) * | 2003-04-11 | 2004-11-18 | Chen Zhang | Voltage tunable photodefinable dielectric and method of manufacture therefore |
US20050153885A1 (en) * | 2003-10-08 | 2005-07-14 | Yun Anthony J. | Treatment of conditions through modulation of the autonomic nervous system |
US20080103209A1 (en) | 2004-04-23 | 2008-05-01 | The Regents Of The University Of California | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists |
EP1604655A1 (de) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie |
US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
NZ581205A (en) | 2005-02-23 | 2011-06-30 | Alza Corp | Intranasal administration of active agents to the central nervous system |
US7452868B2 (en) * | 2005-03-11 | 2008-11-18 | Indevus Pharmaceuticals, Inc. | Controlled release formulations of octreotide |
US20060252685A1 (en) * | 2005-05-04 | 2006-11-09 | Gould Jeffrey D | Treatment for sleep apnea |
AU2006282799B2 (en) * | 2005-08-26 | 2012-11-29 | Healthpartners Research & Education | Methods for treatment of headaches by administration of oxytocin |
CN101404174B (zh) * | 2007-10-04 | 2010-06-09 | 威刚科技股份有限公司 | 电子信息储存装置 |
-
2006
- 2006-08-28 AU AU2006282799A patent/AU2006282799B2/en active Active
- 2006-08-28 WO PCT/US2006/033500 patent/WO2007025249A2/en active Application Filing
- 2006-08-28 CA CA2620202A patent/CA2620202C/en active Active
- 2006-08-28 EP EP09014456.9A patent/EP2179741B1/de active Active
- 2006-08-28 EP EP06813886.6A patent/EP2056800B1/de active Active
- 2006-08-28 US US11/511,569 patent/US20070093420A1/en not_active Abandoned
- 2006-08-28 JP JP2008528234A patent/JP5276982B2/ja active Active
- 2006-08-28 AT AT06802456T patent/ATE458491T1/de not_active IP Right Cessation
- 2006-08-28 EP EP06802456A patent/EP1928484B1/de active Active
- 2006-08-28 JP JP2008528248A patent/JP2009506076A/ja not_active Withdrawn
- 2006-08-28 CA CA002620364A patent/CA2620364A1/en not_active Abandoned
- 2006-08-28 US US11/511,997 patent/US20070054843A1/en not_active Abandoned
- 2006-08-28 US US11/990,878 patent/US20090317377A1/en not_active Abandoned
- 2006-08-28 DE DE602006012513T patent/DE602006012513D1/de active Active
- 2006-08-28 WO PCT/US2006/033672 patent/WO2007025286A2/en active Application Filing
-
2008
- 2008-02-26 IL IL189777A patent/IL189777A0/en unknown
- 2008-09-15 US US12/210,866 patent/US8198240B2/en active Active
-
2009
- 2009-03-23 US US12/409,413 patent/US20100080797A1/en not_active Abandoned
- 2009-03-23 US US12/409,419 patent/US8202838B2/en active Active
-
2011
- 2011-06-21 US US13/165,646 patent/US8258096B2/en active Active
- 2011-10-07 US US13/269,527 patent/US8252745B2/en active Active
-
2012
- 2012-05-24 US US13/480,291 patent/US8501691B2/en active Active
- 2012-07-26 JP JP2012165636A patent/JP2012207046A/ja not_active Withdrawn
- 2012-12-28 JP JP2012286456A patent/JP5670415B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602006012513D1 (de) | Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin | |
DE602004023829D1 (de) | Verfahren zur behandlung von sinuskopfschmerzen | |
TW200639166A (en) | Amino-pyridines as inhibitors of β-secretase | |
EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
WO2012034116A3 (en) | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
WO2011022489A3 (en) | (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders | |
EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
ATE497492T1 (de) | Reinigung von montelukast | |
NI201500031A (es) | Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos. | |
DE602004022424D1 (de) | Proteasominhibitoren und verfahren zu deren anwendung | |
NO20050122L (no) | Prodrug av eksitasjonsaminosyrer | |
EA200970349A1 (ru) | Ингибиторы металлопротеазы гетероциклического происхождения | |
NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
EA200802054A1 (ru) | Ингибиторы фермента | |
CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
ATE527251T1 (de) | Bicyclische derivate als modulatoren von ionenkanälen | |
BR112012018246A2 (pt) | compostos de amida reversa como inibidores de proteína desacetilase e métodos de uso destes | |
ATE429645T1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
DE602005020743D1 (de) | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern | |
DE602006013115D1 (de) | Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung | |
TW200720272A (en) | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | |
EA202091708A1 (ru) | Ингибиторы днк-пк | |
BRPI0414792A (pt) | derivados de ácido 4-(1h-indol-3-il-metilidenoaminóxi-propóxi)-benzóico e compostos relacionados como inibidores de pai-1 para o tratamento de enfraquecimento do sistema fibrinolìtico e de trombose | |
EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
NO20082746L (no) | Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |